Navigation Links
Drug Therapy Boosting Heart-Attack Survival Rates
Date:3/24/2008

10-year study finds less long-term mortality

MONDAY, March 24 (HealthDay News) -- The long-term survival of older Americans who have heart attacks has improved steadily in recent years and apparently is due to the drugs they are prescribed, a new study suggests.

Medicare and pharmacy data on 21,484 residents of New Jersey and Pennsylvania who had heart attacks showed a 3 percent year-by-year reduction in death rates from 1995 to 2004, according to the study.

After adjusting for various factors that could cloud the results, the study authors found that the prescription of drugs such as beta blockers, cholesterol-lowering statins, ACE inhibitors and the like may have been the primary reason for the improvement, said Dr. Soko Setoguchi, associate physician at Brigham and Women's Hospital in Boston, and lead author of the report.

The study doesn't mean that surgical interventions such as artery-opening angioplasty have no place in the long-term treatment of heart attack survivors, Setoguchi said. "The way we looked at it was mortality over time," she said. "What we found was that long-term mortality mainly was less because of medical treatment."

Surgical interventions were relatively uncommon in the group that was studied, Setoguchi said. Only about 25 percent of the heart patients had such interventions, compared to more than 60 percent being prescribed beta blocker drugs, for example, she said.

The findings are published in the April 1 issue of the Journal of the American College of Cardiology.

The study, which had no financial support from the pharmaceutical industry, looked only at prescriptions, not at whether the participants actually took the medications, Setoguchi said. A recent study found that a fairly large percentage of heart attack survivors did not take the medications prescribed for them, and those who didn't fared worse than those who did.

"If you don't take the medication, you don't get the benefit," Setoguchi said.

Surgical intervention, such as angioplasty, clearly has a role in the early treatment of heart attack, said Dr. David J. Maron, associate professor of medicine and emergency medicine at Vanderbilt University, and co-author of an accompanying editorial in the journal. The new report covered survival only after the first 30 days of a heart attack, he noted.

"We know that PCI [percutaneous coronary intervention, or angioplasty] improves survival in the acute phase of a heart attack," Maron said. "The best short-term therapy is reperfusion, preferably with PCI. As a complement to that, there needs to be long-term therapy for atherosclerosis."

Reperfusion is restoration of blood flow to the heart. Atherosclerosis is the artery-hardening process that leads to blockage of blood vessels.

Setoguchi agreed. A separate analysis of in-hospital deaths in the group of patients studied showed that "increased use of PCI might have explained the improvement in short-term mortality," she said.

Dr. William E. Boden, professor of medicine and public health at the State University of New York at Buffalo, called the study valuable, even though it had limitations. For instance, it only included residents of two states and left out data on survival in the first 30 days after a heart attack, he said.

"But I don't think those limits invalidate the study," Boden said. "This is a very important observation, because we tend to under-treat the elderly. Often we intuit that these medications are too little, too late, so why bother. The study stresses that these are higher-risk patients, and medications should be used as aggressively in older patients as in younger patients."

More information

The U.S. National Heart, Lung, and Blood Institute describes medications used to prevent and treat heart attacks.



SOURCES: Soko Setoguchi, M.D., Dr.P.H., associate physician, Brigham and Women's Hospital, Boston; David J. Maron, M.D., associate professor of medicine and emergency medicine, Vanderbilt University, Nashville; William E. Boden, M.D., professor of medicine and public Health, State University of New York at Buffalo; April 1, 2008, Journal of the American College of Cardiology


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. ClearScript Offers Innovative Medication Therapy Management Program to Employee Health Plans
2. Medical Manufacturer TomoTherapy Implements SAP Solution in Only 16 Weeks
3. Breast Cancer Radiation Therapy Works in Fewer, But Higher Doses
4. Siemens Consortium to Construct Particle Therapy Center at the University Clinic of Schleswig-Holstein
5. Therapy Could Save Limbs After Frostbite
6. Researchers study new drug and indications for heated chemotherapy treatment
7. Radioimmunotherapy After Chemo Safe for Common Lymphoma
8. Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients
9. Gene therapy could save kids from a lifetime of eating cornstarch
10. Combined stenting and photodynamic therapy improves survival in late stage liver cancer patients
11. Cardiac effects associated with breast cancer treatment appear lower with dose-dense chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... , ... February 24, 2017 , ... Yisrayl Hawkins, Pastor ... on Bible Prophecy concerning this present generation. Yisrayl makes an astounding statement when ... generation. He explains that the Bible details the current times so plainly that ...
(Date:2/24/2017)... ... February 24, 2017 , ... ... Senior International Elite division on February 12th. Ms. Esparza qualified into this ... elite qualifier competition held in Las Vegas, Nevada. Frida is one of approximately ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... exclusively to funding innovative lymphoma research and serving the lymphoma community through a ... to the La Gorce Country Club in Miami Beach to host its Swirl: ...
(Date:2/23/2017)... ... 23, 2017 , ... Rosica Communications, a national PR ... media management, corporate communications, SEO and cause marketing, is opening an office in ... Hampshire, Massachusetts and Canada, Rosica will focus on expanding its footprint. , ...
(Date:2/23/2017)... ... , ... ERT, a global data and technology company that ... leading clinical development service provider, has selected ERT’s Trial Oversight suite as its ... to an array of circumstances including the use of multiple data capture modalities ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... 24, 2017 Zimmer Biomet Holdings, Inc. (NYSE ... will present at the Cowen and Company 37 th ... Copley Place on Tuesday, March 7, 2017 at 11:20 ... of the presentation can be accessed at http://wsw.com/webcast/cowen38/zbh ... the conference via Zimmer Biomet,s Investor Relations website at ...
(Date:2/24/2017)... Research and Markets has announced the addition of the "Hemophilia Drugs ... ... Price Analysis and Strategies - 2016, provides drug pricing data and benchmarks ... What are the key drugs marketed for ... Hemophilia market? What are the unit prices and annual ...
(Date:2/24/2017)... HARRISBURG, Pa. , Feb. 24, 2017 ... Secretary of Drug and Alcohol Programs Jennifer Smith ... role in providing training for and using naloxone, a ... Mark McCullough , a recovery specialist and overdose ... naloxone by EMS providers. "A significant part ...
Breaking Medicine Technology: